$72.5 Million is the total value of ACT CAPITAL MANAGEMENT, LLC's 71 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DVN | DEVON ENERGY CORP NEW | $4,961,000 | +9.1% | 82,500 | 0.0% | 6.85% | +7.7% | |
| ENVVENO MED CORP | $2,520,000 | +66.1% | 401,200 | 0.0% | 3.48% | +63.9% | ||
| ET | ENERGY TRANSFER L P | $1,410,000 | +10.6% | 127,800 | 0.0% | 1.95% | +9.1% | |
| IKT | INHIBIKASE THERAPEUTICS INC | $853,000 | +22.6% | 937,500 | 0.0% | 1.18% | +21.0% | |
| AFMD | AFFIMED N V | $636,000 | -25.6% | 308,800 | 0.0% | 0.88% | -26.6% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $469,000 | -6.2% | 62,500 | 0.0% | 0.65% | -7.4% | |
| ICAD | ICAD INC | $431,000 | -47.4% | 205,000 | 0.0% | 0.60% | -48.1% | |
| VIST | VISTA OIL &GAS SAB DE CV SPON ADS EACH REP 1 ORD SHS SER Asponsored ads | $391,000 | +27.4% | 41,500 | 0.0% | 0.54% | +25.9% | |
| OCX | ONCOCYTE CORPORATION | $241,000 | -18.9% | 330,000 | 0.0% | 0.33% | -19.8% | |
| LPTX | LEAP THERAPEUTICS INC | $233,000 | -23.6% | 265,000 | 0.0% | 0.32% | -24.6% | |
| ONCT | ONCTERNAL THERAPEUTICS INC | $187,000 | -19.7% | 210,000 | 0.0% | 0.26% | -20.9% | |
| CRDF | CARDIFF ONCOLOGY INC | $186,000 | -29.8% | 120,600 | 0.0% | 0.26% | -30.7% | |
| SURF | SURFACE ONCOLOGY INC | $177,000 | -36.8% | 170,500 | 0.0% | 0.24% | -37.8% | |
| MRKR | MARKER THERAPEUTICS INC | $131,000 | +12.0% | 354,400 | 0.0% | 0.18% | +10.4% | |
| NLTX | NEOLEUKIN THERAPEUTICS INC | $127,000 | -38.0% | 199,000 | 0.0% | 0.18% | -39.0% | |
| MDNA | MEDICENNA THERAPEUTICS CORP | $124,000 | -28.3% | 149,070 | 0.0% | 0.17% | -29.3% | |
| GRTS | GRITSTONE BIO INC | $122,000 | +6.1% | 47,500 | 0.0% | 0.17% | +4.3% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $97,000 | -36.6% | 90,000 | 0.0% | 0.13% | -37.4% | |
| DRAGANFLY INC | $95,000 | -22.1% | 135,000 | 0.0% | 0.13% | -23.4% | ||
| YCBDPRA | CBDMD INC8% ser a cum pfd | $77,000 | -3.8% | 22,000 | 0.0% | 0.11% | -5.4% | |
| ENLV | ENLIVEX THERAPEUTICS LTD | $64,000 | -5.9% | 15,000 | 0.0% | 0.09% | -7.4% | |
| SDPI | SUPERIOR DRILLING PRODS INC | $54,000 | -31.6% | 80,000 | 0.0% | 0.08% | -31.8% | |
| CTSO | CYTOSORBENTS CORP | $48,000 | -37.7% | 35,000 | 0.0% | 0.07% | -38.9% | |
| OYST | OYSTER PT PHARMA INC | $48,000 | +29.7% | 8,500 | 0.0% | 0.07% | +26.9% | |
| TCON | TRACON PHARMACEUTICALS INC | $48,000 | -15.8% | 28,500 | 0.0% | 0.07% | -17.5% | |
| YALA | YALLA GROUP LTDads | $44,000 | -17.0% | 13,500 | 0.0% | 0.06% | -17.6% | |
| SIOX | SIO GENE THERAPIES INC | $41,000 | -22.6% | 146,500 | 0.0% | 0.06% | -23.0% | |
| SQZ | SQZ BIOTECHNOLOGIES CO | $36,000 | -29.4% | 16,000 | 0.0% | 0.05% | -29.6% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $36,000 | -18.2% | 12,000 | 0.0% | 0.05% | -19.4% | |
| CYT | CYTEIR THERAPEUTICS INC | $29,000 | -35.6% | 15,000 | 0.0% | 0.04% | -36.5% | |
| YCBD | CBDMD INC | $28,000 | -49.1% | 125,000 | 0.0% | 0.04% | -49.4% | |
| BLRX | BIOLINE RX LTDsponsored ads | $25,000 | -28.6% | 27,500 | 0.0% | 0.04% | -28.6% | |
| TIL | INSTIL BIO INC | $24,000 | +4.3% | 5,000 | 0.0% | 0.03% | +3.1% | |
| ARAV | ARAVIVE INC | $15,000 | -21.1% | 18,777 | 0.0% | 0.02% | -22.2% | |
| AIRSCULPT TECHNOLOGIES INC | $10,000 | +11.1% | 1,500 | 0.0% | 0.01% | +7.7% | ||
| RNAZ | TRANSCODE THERAPEUTICS INC | $7,000 | -12.5% | 6,500 | 0.0% | 0.01% | -9.1% | |
| GTH | GENETRON HOLDINGS LIMITEDads | $6,000 | -53.8% | 7,500 | 0.0% | 0.01% | -55.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STAAR SURGICAL CO | 6 | Q3 2022 | 22.7% |
| ARROWHEAD PHARMACEUTICALS INC | 6 | Q3 2022 | 10.1% |
| ARCTURUS THERAPEUTICS HLDGS | 6 | Q3 2022 | 12.8% |
| CLEARSIDE BIOMEDICAL INC | 6 | Q3 2022 | 7.7% |
| KRYSTAL BIOTECH INC | 6 | Q3 2022 | 5.6% |
| FUBOTV INC | 6 | Q3 2022 | 4.4% |
| EIGER BIOPHARMACEUTICALS INC | 6 | Q3 2022 | 2.4% |
| ASPIRA WOMENS HEALTH INC | 6 | Q3 2022 | 3.3% |
| ICAD INC | 6 | Q3 2022 | 2.0% |
| INHIBIKASE THERAPEUTICS INC COM | 6 | Q3 2022 | 1.7% |
View ACT CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HyreCar Inc. | December 09, 2020 | 230,000 | 1.3% |
| SOLIGENIX, INC. | February 07, 2020 | 1,221,499 | 5.6% |
| EDISON NATION, INC. | April 18, 2019 | 214,454 | 3.8% |
| Hancock Jaffe Laboratories, Inc. | December 26, 2018 | 503,500 | 4.3% |
| Ampio Pharmaceuticals, Inc. | August 10, 2018 | 1,210,785 | 1.4% |
| Xspand Products Lab, Inc. | May 09, 2018 | 405,000 | 9.3% |
| CROSSROADS SYSTEMS INC | June 16, 2017 | 59,053 | 4.8% |
| ALLDIGITAL HOLDINGS, INC.Sold out | January 23, 2017 | 0 | 0.0% |
| MOBIVITY HOLDINGS CORP. | January 06, 2017 | 1,734,916 | 4.8% |
| Akers Biosciences Inc | January 25, 2016 | 213,500 | 3.9% |
View ACT CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-11 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-16 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2020-12-09 |
| SC 13G/A | 2020-02-10 |
| SC 13G/A | 2020-02-07 |
| SC 13G/A | 2020-02-07 |
View ACT CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.